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ttp://dx.doi.org/10.1016/j.ajpath.2013.05.033Triple-negative breast cancers (TNBCs) are a diverse and heterogeneous group of tumors that by
deﬁnition lack estrogen and progesterone receptors and ampliﬁcation of the HER2 gene. The majority of
the tumors classiﬁed as TNBCs are highly malignant, and only a subgroup responds to conventional
chemotherapy with a favorable prognosis. Results from decades of research have identiﬁed important
molecular characteristics that can subdivide this group of breast cancers further. High-throughput
molecular analyses including sequencing, pathway analyses, and integrated analyses of alterations at
the genomic and transcriptomic levels have improved our understanding of the molecular alterations
involved in tumor development and progression. How this knowledge should be used for rational
selection of therapy is a challenging task and the subject of numerous ongoing research programs. This
review summarizes the current knowledge on the clinical characteristics and molecular alterations of
TNBCs. Currently used conventional therapeutic strategies and targeted therapy studies are discussed,
with references to recently published results on the molecular characterization of TNBCs. (Am J Pathol
2013, 183: 1064e1074; http://dx.doi.org/10.1016/j.ajpath.2013.05.033)Supported in part by the KG Jebsen Foundation, The Norwegian Cancer
Society, The Norwegian Radium Hospital Foundation, and The Norwegian
Breast Cancer Society/The Pink Ribbon Movement Norway.
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This article is part of a review series on the molecular pathogenesis of
breast cancer.Breast cancers show extensive heterogeneity despite their
common tissue of origin. Decades of research in molecular
pathology and molecular genetics have shown a number of
distinct subtypes. Currently, only a limited number of clinical,
pathologic, and molecular factors help clinicians make deci-
sions on therapy selection and help evaluate prognosis at the
time of diagnosis. Breast tumors are categorized into three
main groups based on markers that reﬂect available treatment
options: estrogen receptor (ER) or progesterone receptor
positive, erbB2 ampliﬁed (HER2 positive) with and without
ER/progesterone receptor, and triple-negative breast cancer
(TNBC) deﬁned by the absence of ER/progesterone receptor
expression and HER2 ampliﬁcation. Targeted therapy is
available for patients with ER-positive and patients with
HER2-positive tumors, leaving those with triple-negative
(TN) disease as the only group of patients presentlywithout an
option for targeted therapy.
High-throughput molecular analyses have led to the
discovery of distinct subtypes of breast cancer, which partlystigative Pathology.
.correspond to the histopathologic entities described above.
The ﬁrst gene expressionebased classiﬁcation was per-
formed more than a decade ago,1,2 and identiﬁed ﬁve dif-
ferent subgroups that are biologically diverse with different
clinical outcomes: two luminal-cellerelated groups (luminal
A and luminal B), a myoepithelial-cellerelated group (basal-
like), a HER2-enriched group, and a normal-like group. A
minimal gene set of 50 genes (Pam50) has been developed
for classifying subtypes of breast cancer with high agreement
in classiﬁcation with the larger intrinsic gene sets originally
used for subtyping.3 This subgrouping has proven robust and
has provided important insight into the biology of breast
Figure 1 Distribution of subtypes and outcome
in the METABRIC cohort.9 A: Distribution of PAM50
subtypes in triple negative breast cancer (TNBC)
(nZ 252): 86.1% basal-like, 7.1% HER2-E), 4.8%
normal-like, 2.0% luminal A (dark blue), and 0%
luminal B. PAM50 subtypes were assigned from
gene expression analysis as previously described.9
B: Distribution of histopathologic groups in
basal-like breast cancer (n Z 321): 67.6% triple
negative (TN), 15.3% ERþ/HER2, 11.8% ER/
HER2þ, 2.5% ERþ/HER2þ. C: Breast cancere
speciﬁc survival by PAM50 subtypes in 1924 inva-
sive breast carcinomas with 15 years of follow-up
evaluation: luminal A, luminal B, basal-like, HER2-
E, and normal-like. D: Breast cancerespeciﬁc
survival by histopathologic grouping in 1893 inva-
sive breast carcinomas: TN, ERþ, and HER2þ
including both progesterone receptor (PR)þ and
PR, ERþ, and HER2 including both PRþ and
PR, and ER and HER2þ including both PRþ
and PR. Cases that were ER, PRþ, and HER2
(n Z 35) were excluded from this analysis. ER
status was determined by immunohistochemical
scoring, PR status was derived from gene
expression arrays, and HER2 gene ampliﬁcation
status was based on scoring of array copy number
analysis. PR, progesterone receptor.
TNBC and Therapeutic Targetscancer. However, methods for assigning a subtype to single
samples have proven challenging and the methods are
debated.4e7 The basal-like and luminal carcinomas have
different etiologies and for most purposes may be considered
distinct diseases. Because the biology of these subtypes is
substantially different, stratiﬁcation is essential both for
clinical and preclinical studies to identify common features of
tumorigenesis that can be used for further therapy selection.
The majority of basal-like tumors are TN, but not entirely,
and further molecular proﬁling has shown extensive hetero-
geneity of both TNBC and basal-like tumors, which is of
possible importance for treatment decisions. In this review
the heterogeneity of TNBC/basal-like breast tumors is dis-
cussed, with a focus on the underlying molecular alterations
of potential importance for developing targeting therapies.Clinical Characteristics of TNBC
The fraction of TNBC is variable and has been reported to be in
the range of 9% to 16%.8e12 TNBC is known to be more
frequent in younger patients, inBRCA1mutation carriers, and in
speciﬁc ethnic groups (African American and Hispanic wom-
en).12e15 Compared with Caucasians, African American
women are twice as likely to develop TNBC, suggesting that
germline genetic background is of major importance for the
transcriptional program and tumor differentiation.12,13,16 The
majority of TNBC tumors, when classiﬁed by tumor mor-
phology, are invasive ductal carcinomas (approximately 90%),
with the rest classiﬁed as apocrine, lobular, adenoid cystic, and
metaplastic.11 Patients with TNBC often have unfavorableThe American Journal of Pathology - ajp.amjpathol.orghistopathologic features at diagnosis because they are of higher
histologic grade, larger tumor size, and more often are lymph
node positive.17
The basal-like subtype by gene expression most frequently
is TN, but not always. Figure 1, A and B, shows the overlap
between the basal andTNsubtypes among cases from the large
METABRIC cohort.9 Of 252 TN tumors, 86.1% were basal-
like, 7.1% were HER2-enriched, 4.8% were normal-like,
and 2.0% were luminal A, illustrating the heterogeneity of
TNBCs with respect to Pam50 subtypes (Figure 1A). Other
investigators have reported a fraction of basal-like TN tumors
of 72% to 79%.18,19 Differences possibly could be owing
to cohort selection or methodologic issues.4,20 Conversely,
basal-like tumors by gene expression (n Z 321) are most
frequently TNBCs (67.6%), but 15.3% are ERþ/HER2,
11.8% are ER/HER2þ, and 2.5% are ERþ/HER2þ
(Figure 1B). This lack of consistency between gene expression
subtypes and standard markers has motivated several studies
to reﬁne classiﬁcation by immunohistochemistry using ad-
ditional markers. Expression of either cytokeratin 5/6 or
epidermal growth factor receptor (EGFR) has been shown to
identify basal-like tumors classiﬁed by gene expres-
sion.8,13,21,22 Several investigators thus have used these as
surrogate markers for a core basal subgroup (ER, proges-
terone receptor, HER, cytokeratin 5/6þ, and EGFRþ).
Basal-like breast cancer has been shown to have an infe-
rior prognosis compared with luminal subtypes in several
studies.2,4 In the recentMETABRIC study this was conﬁrmed,
and Figure 1, C and D, show breast cancerespeciﬁc survival
with 15 years of observation for the Pam50 subtypes
and histopathologic groups, respectively. In this cohort, the1065
Engebraaten et alHERþ/HER2-enrichedgroup of patients had a poor prognosis,
of whom none received HER2-targeted therapy. Basal-like
tumors and TNBC have high breast cancer mortality the ﬁrst
few years after diagnosis, but then reach a plateau, suggesting
that patients surviving the ﬁrst high-risk phase are cured of the
disease. This is in contrast to luminal disease, in which breast
cancer mortality is constant over time (up to 15 years after
diagnosis), as observed in several cohorts. With extended
observation time after diagnosis the curves cross, leading to
a higher risk of breast cancer death in luminal tumors.8,23
Although most TNBCs are found in younger women, approx-
imately 25% of the TN patients are 65 years, and because
older patients are less likely to receive systemic treatment, this
represents a subset of patients with aggressive disease and poor
outcome.24 It is known that African American women have
a higher mortality rate from breast cancer, which potentially is
explained by the higher incidence of TNBC.25 However, no
clear racial effect has been identiﬁed within TNBC.26
Prognosis is related closely to metastatic behavior and
breast cancer subtypes are linked to different sites of metas-
tases. Bone is the overall most common metastatic site,
except in basal-like disease, which is dominated by brain,
lung, and distant lymph node metastases.27,28 TN nonbasal
tumors showed a similar pattern to basal tumors, but with
more liver metastases.
Molecular Characteristics of TNBC
Gene Expression Analysis of TNBCs by Microarrays
Gene expression analysis by microarrays was introduced
more than a decade ago and has provided a basis for
a comprehensive description of individual tumors and insight
into the vast intertumor heterogeneity. Still, the classiﬁcation
derived from the intrinsic gene set2 represents the basis for
biological understanding of breast cancer with the luminal
subtypes characterized by expression of estrogen receptor 1
and genes expressed by luminal epithelial cells, and the
nonluminal subgroups (basal-like and HER2-enriched)
characterized by expression of genes associated to basal/
myoepithelial cells. The separation of luminal and non-
luminal tumors has proven robust across most data sets.
Basal-like tumors were referred to as basal because of their
expression of genes typically expressed in basal epithelial
cells, such as cytokeratin 5, 6, or 17. These tumors are highly
proliferative and frequently TP53mutated. Basal-like tumors
are associated with BRCA1 mutation status because the
majority of BRCA1 germline mutation carriers develop basal-
like breast cancer.14 This has led to the concept of BRCA-
ness, tumors that share features of deregulated DNA repair by
deﬁciency in homologous recombination with BRCA inac-
tivated tumors from BRCA mutation carriers.29 It is believed
that the combined TP53, RB, and BRCA1 pathways loss of
activity is responsible for the high level of genomic insta-
bility observed in basal-like tumors.30 A fraction of TN
tumors belong to the HER2-enriched gene expression1066subtype (Figure 1A) without HER2 gene ampliﬁcation, but
with an expression pattern associated with HER2 signaling
with possible mutations in HER2 or downstream targets.30
These patients do not receive any HER2-targeted treatment
with the present accepted treatment recommendations based
on the results in clinical trials, but the expression pattern
suggests that they might beneﬁt from treatment targeting
relevant signaling pathways.
Further reﬁnement of the intrinsic subgroups has identi-
ﬁed the claudin-low group, which is characterized as TN
with a low expression of claudin 3, 4, and 7 tight junction
proteins and E-cadherin.31 These were described to express
mesenchymal expression features, with a low level of
luminal genes and high expression of endothelial cell and
lymphocyte markers. The tumors are enriched for epithelial-
mesenchymal transition (EMT) markers and resemble
mammary epithelial stem cells. In survival analyses the
claudin-low group had an intermediate outcome compared
with luminal and basal tumors, and an intermediate response
to chemotherapy.32
The heterogeneity of TNBCs is widely acknowledged. In
a study of 97 TN cases all tumors were found to be basal-like,
but hierarchical clustering of gene expression revealed ﬁve
subgroups.33 A comprehensive characterization of 51 breast
cancer cell lines showed that the transcriptional proﬁle re-
ﬂected primary breast tumors, except that more and higher
levels of ampliﬁcations were seen.34 Basal-like cell lines
could be separated into two groups: basal A resembles basal-
like, and basal B has amore stem cellelike expression proﬁle.
The most extensive study of gene expression in TNBCs to
date was performed by Lehmann et al35 and compiled a data
set of 587 TNBC gene expression proﬁles from 21 published
studies. Clustering analysis of the most differentially ex-
pressed genes identiﬁed seven subgroups: basal-like 1, basal-
like 2, immunomodulatory, mesenchymal, mesenchymal
stemelike, luminal androgen receptor, and an unstable cluster
that was not classiﬁed. Basal-like 1 and basal-like 2 were
highly proliferative and had a higher expression of cell-cycle
and DNA damage response genes. The mesenchymal and
mesenchymal stemelike groups were enriched for EMT
genes, whereas the immune-modulatory subtype was char-
acterized by immune cell signaling features. The luminal
androgen receptor subtype was ER negative, but enriched in
hormone-related pathways and found to be androgen recep-
toreexpressing, suggesting a role for anti-androgenic treat-
ment for these cases. However, in a recent neoadjuvant study,
androgen-receptor expression in TNBC was associated with
a favorable prognosis36 and the biological relevance of
androgen receptor in breast cancer and the potential role in
therapy is debated.37
Copy Number Aberrations in TNBC Resulting from
Genomic Instability
Copy number aberrations resulting from genomic instability
is a key feature in the transformation of malignant cells,ajp.amjpathol.org - The American Journal of Pathology
Table 1 Top Mutated Genes in TNBC
Gene
Shah et al41
(n Z 65)
Stephens et al47
(n Z 14)
TCGA10
(n Z 86)
n % n % n %
TP53 35 53.8 12 85.7 68 79.1
PIK3CA 7 10.8 3 21.4 9 10.5
USH2A 6 9.2 1 7.1 9 10.5
TTN 6 9.2 8 57.1
RB1 5 7.7 2 14.3 4 4.7
DST 2 3.1 5 35.7
MLL3 2 3.1 1 7.1 3 3.5
MYO3A 6 9.2
PTEN 5 7.7 1 1.2
SYNE1 4 6.2 2 14.3
TCGA, The Cancer Genome Atlas Network.
TNBC and Therapeutic Targetsleading to DNA translocations, deletions, and ampliﬁcation.
Array comparative genomic hybridization analysis of
tumors provides genome-wide information of DNA copy
number. The frequency of copy number alterations is found
to differ between intrinsic subtypes.38 Basal-like tumors
show a high degree of genomic instability with recurrent
copy number alterations being losses on 3q, 4p/q, 5q, 12q,
and 14q, and gains on 1q, 3q, 6p, 7q, 8q, 10p, 17q, and
21q.38e40 Some of the most frequently observed copy
number alterations in TNBCs are affecting cancer-associated
genes such as RB1, PTEN, EGFR, and PARK2.41 Although
extensive genomic instability is frequent in basal-like tumor
genomes, a subset do not have such alterations, suggesting
different mechanisms of carcinogenesis even within
TNBC.42
The global patterns of chromosomal rearrangements can
be used to group tumors as simple, complex sawtooth, and
complex ﬁrestorm,43 with patients whose tumors contain
complex alterations experiencing an inferior outcome.43 A
more detailed characterization of such patterns quantiﬁed
alterations of whole chromosomal arms and complex chro-
mosomal rearrangements with two indices: whole-arm
aberration index and complex arm aberration index.44
Cases with a high complex arm aberration index score of
complex genomic events, frequently basal-like, showed an
increased risk for breast cancerespeciﬁc death, as compared
with low complex arm aberration index tumors.
A challenge in analysis of chromosomal aberrations is the
fact that a tumor is an admixture of tumor (aberrant) and
normal (nonaberrant) cell fractions and that tumor ploidy
usually is unknown. The allele-speciﬁc copy number anal-
ysis of tumors algorithm that deduces tumor ploidy showed
that basal-like tumors have a signiﬁcantly higher loss of
heterozygosity and loss of genomic material during tumor
development, followed by a duplication of the genome,
resulting in near-triploid basal-like tumors.45 This suggests
that basal-like tumors tend to follow a progression path with
an initial unstable hypodiploid state followed by whole-
genome duplication. Because this pattern is different from
the other subtypes it alludes to the importance of genomic
instability in the pathogenesis of basal tumors. Sequencing
single cells from two metastatic TNBCs showed that selected
subclones were dominated by extensive loss of DNA, again
suggesting the importance of a hypodiploid stage in basal-
like tumor progression.46 The translocation pattern of
somatic rearrangements in 24 breast cancers (of which 6
tumors and 6 cell lines were TN) was studied using paired-
end sequencing.47 Most of these were intrachromosomal, as
compared with interchromosomal translocations, most
commonly tandem duplications, although diversity was
observed within TN cancers. The ploidy distribution in basal-
like tumors and the speciﬁc translocation pattern together
may suggest a unique path of progression for TNBCs.45,48,49
Combined copy number aberrations and gene expression
has been used in a study of 2000 cases for classiﬁcation and
categorization of breast cancer, with the major ﬁnding ofThe American Journal of Pathology - ajp.amjpathol.org10 integrative cluster groups.9 Most of the TNBCs were
classiﬁed in integrative cluster 10, representing the core
basal subgroup in this new classiﬁcation. The highest rate of
TP53 mutations was found in integrative cluster 10
combined with intermediate levels of genomic instability,
loss of 5q, and gains at 8q, 10p, and 12p.9,50 Loss of 5q has
been associated with the presence of a TP53 mutation,50 and
a basal-speciﬁc gene expression pattern linked with cell-
cycle checkpoint control, DNA damage repair, and
apoptosis.51 Approximately 25% of TNBCs were assigned to
integrative cluster 4, consisting of both ERþ and ER
tumors. This subgroup has a good outcome, a low level of
genomic instability, rearranged T-cell receptor, and extensive
lymphocytic inﬁltration.51 The pathway recognition algo-
rithm using data integration on genomic models is a method
that integrates molecular data from different genomic levels
(copy number, methylation, miRNA, and mRNA expression)
within a pathway-speciﬁc framework.52 This approach has
proven powerful because crucial pathways for tumor
sustainability and evolution tend to be perturbed by a range of
mechanisms and thus a pathway-based approach helps to
decipher important regulators. In breast cancer this has led to
identiﬁcation of ﬁve clusters of tumors mostly separated by
immune-related signaling pathways.53 Basal-like tumors
were split into two groups with differences in survival by their
ratio of T-helper 1 and cytotoxic T-lymphocyte gene signa-
ture to the level of T-helper 2eassociated humoral immunity
signature, both with high FOXM1 signaling. Because per-
turbed immune signatures were the dominating factor in this
pathway-driven stratiﬁcation of breast tumors, it shows the
importance of interaction between tumor and stromal cells
and the complicated role of immune response in cancer.
Somatically Acquired Mutations in TNBC
Somatically acquired mutations in tumor DNA varies exten-
sively from tumor to tumor.54 The genes most frequently
foundmutated in three recent sequencing studies in TNBC are
summarized in Table 1.10,41,54 Somatic mutations of TP53 are
found in the majority of TN tumors (53.8% to 85.7%), and1067
Engebraaten et alwhen combined with inferred pathway analysis there is
evidence for loss of TP53 function in nearly all basal-like
tumors.10 Interestingly, TP53 mutations in basal-like tumors
were more of the nonsense and frame-shift type, in contrast to
mutations in luminal tumors that more frequently were
missense. Shah et al41 found that approximately 20% of cases
had potential clinical druggable aberrations (ie, which may be
inhibited by existing clinically used drugs) including BRAF
V600E, EGFR ampliﬁcations, and ERBB2/ERBB3mutations.
Integrative pathway analysis comparing basal-like and lu-
minal tumors identiﬁed hyperactivated FOXM1 as a tran-
scriptional driver of proliferation and found increased MYC
and HIF1-a/ARNT as key regulators.10 Integrative pathway
analysis also conﬁrmed that loss ofRB1 andBRCA1 are basal-
like features.
Sequencing studies55,56 have shown that mutations are
introduced continuously during tumor evolution, resulting in
numerous subclones. Timing these events is possible by
taking both mutational frequency and copy number alter-
ations into account. TP53 were found to frequently occur in
most clones in the tumors, indicating an early event critical for
tumorigenesis, and more rarely in smaller subclones, indi-
cating a late event and hence probably less important in tumor
development. Overall, basal TN had more subclonal pop-
ulations than the nonbasal TNBCs. The subclones populate
the tumor in a dynamic process in which the clone with the
best selective advantage dominates. Treatment provides
a selective pressure on the tumor and although chemotherapy
may eradicate the bulk of the tumor, it could at the same time
provide an opportunity for a subclone to proliferate and ulti-
mately induce treatment resistance. Unless successfully
treated, the genetic diversiﬁcation in tumor cells does not stop,
but is an ongoing process continued in the development of
tumor metastases. This was addressed in a recent publica-
tion57 on DNA and RNA sequencing of advanced (recurrent
or metastatic) tumors from 14 patients with TN disease.
Expression proﬁles associated with genes regulating cell-
cycle control, G2-M checkpoint, and mitosis were seen in 8
of these tumors, and expression patterns were enriched for
immune-related pathways in 5 tumors.57 A single tumor was
enriched for genes involved in androgen and ERmetabolism.
The most commonly mutated gene, TP53, was detected in 10
of the tumors. Alterations involving the RAS/RAF/MEK/
ERK pathways or the PI3K/AKT/mTOR pathways were
found in nine patients, which is of considerable interest from
a therapeutic perspective. In addition, FOXM1 genes were
found overexpressed in 12 of the tumors, highlighting the
importance of gene regulation of factors involved in the
proliferation of cell-cycle and mitotic check point control.
Current and Future Therapy of TNBC
Therapy of TNBC is based on surgery, radiotherapy, and
chemotherapy (Figure 2A), because currently there are no
targeted treatment options are available. The most active
cytotoxic agents are anthracyclines and taxanes. Large clinical1068studies and meta-analyses have shown survival beneﬁt in both
hormone receptorepositive and hormone receptorenegative
tumors with anthracyclines.58 The rate of pathologic complete
response after neoadjuvant treatment in hormone receptore
negative tumors is higher compared with hormone receptore
positive tumors, and pathologic complete response has been
shown to be predictive for outcome (recurrence-free sur-
vival).59,60 A study combining data from seven neoadjuvant
prospective clinical trials investigated the relationship between
clinical subtypes, pathologic complete response, and RFS in
4193 of these patients.59 A pathologic complete response,
deﬁned here as the absence of invasive breast cancer in the
breast and lymph nodes, was achieved in 36% of the patients
undergoing therapy with anthracyclines and taxanes. A
summary of recent neoadjuvant clinical trials and data sets in
patients with TNBC is shown in Figure 3.59,61e74
For therapy of TNBC, regimens other than standard
anthracycline- and taxane-basedmay be of value (Figure 2A).
Genetic instability associated with TNBC indicates that
DNA interacting agents may be advantageous. Studies with
cisplatin in combination with anthracyclines have shown
activity in the adjuvant setting, butwere not designed to detect
or verify the superiority of platinum regimens in TNBC.70
Other studies also have reported the activity of such combi-
nations.75 In a more recent study, the beneﬁt of adjuvant
cisplatin-containing therapy was similar to other commonly
used regimens, but the outcome was not reported speciﬁcally
for TNBC.76 Recently, a neoadjuvant study of TNBC did not
show an additional beneﬁt of adding carboplatin to the stan-
dard treatment of anthracycline followed by taxane.71 A few
studies have reported the use of carboplatin with paclitaxel or
docetaxel, without anthracyclines, in the neoadjuvant setting
(Figure 3), with similar response rates to previous studies, but
with a limited number of patients.72e74 Although platinum-
containing treatment regimens are active in breast cancer,
there is no general evidence for superiority in TNBC.
Tumors associated with inactivated BRCA, as in BRCA1/2
mutation carriers, may be candidates for platinum-containing
therapy owing to the lack of BRCA protein function in
homologous DNA recombination-mediated repair, making
the cells dependent of the more error prone end-joining DNA
repair mechanism (Figure 2, A and B). A high response rate
has been reported, but the study was small (Figure 3), and the
role of platinum in this subset of patients is debated.77 Simi-
larly, somatic inactivation of BRCA function has been
described in basal-like breast cancers, and therefore could be
a candidate for DNA-acting platinum-containing chemo-
therapy. However, recent neoadjuvant studies in patients with
basal-like tumors have not conﬁrmed this (Figure 3). Studies
using speciﬁc signatures to predict the outcome of high-dose
alkylating chemotherapy may indicate that some TNBCs
could be responders to alkylating therapy.78 Evidently, TNBC
cannot be considered a single entity. Predictive markers of
response to chemotherapeutic regimens may be patterns of
DNA rearrangements, mutation patterns, or defective DNA
repair mechanisms; hence, molecular analyses should beajp.amjpathol.org - The American Journal of Pathology
Figure 2 Currently used therapies and molecular targets for therapy in triple negative breast cancer (TNBC). A: Currently used therapy for TNBC includes
anthracyclines, taxanes, andplatinum-based agents (most commonly carboplatin and cisplatin). Themechanismsof actionare indicated, and rational combinations of
these therapies with new targeted treatment principles are investigated that may combat treatment resistance and increase therapeutic efﬁcacy (eg, antiangiogenic
therapy and platinum/PARPi). B: Molecular targeted therapies for TNBC have been studied involving multiple pathways, and druggable targets are exempliﬁed in the
ﬁgure. The different principles investigated are highly integrated, which may generate a rationale for combining different therapeutic approaches in the future. Of
speciﬁc interest are future combinations involving chemotherapeutic agents (A) with targeted therapeutics because of the documented activity of the conventional
treatment regimens. BE, base excision repair pathway; HR, homologous end-joining repair pathway; NHEJ, nonhomologous end-joining repair pathway. Printed with
permission from Kari C. Toverud (copyright holder).
TNBC and Therapeutic Targetsincluded in all preclinical and clinical trials for identiﬁcation
of relevant predictive factors in speciﬁc tumor types.Molecular-Directed Therapy in TNBC
As reviewed above, a number of studies using high-throughput
molecular technologies including deep sequencing have
paved the way for a more rational selection of therapeutics in
TNBC according to the molecular characteristics of the tumor
itself (as shown in Figure 2B). A total of 121 studies on TNBC
therapy were found in http://www.clinicaltrials.gov (last
accessed at the time of the submission,April 5, 2013), using the
search term “triple negative breast cancer,” limiting the search
to phase II and III intervention studies, or phase I studies only
recruiting breast cancer patients, of which 77 were based onThe American Journal of Pathology - ajp.amjpathol.orga targeted principle. The list is not exhaustive but provides an
overview of agents currently in clinical trials in TNBC. The
role of vascular endothelial growth factor inhibition (26
studies), poly (ADP-ribose) polymerase (PARP) inhibition (11
studies, of which 5 studies were on iniparib), erbB inhibition
(14 studies), and phosphatidylinositol 3-kinase/AKT/mTOR
targeted therapies (9 studies) in TNBC still are not settled,
although someactivity has been reported. In addition, a number
of compounds are in early phase clinical trials, and are expected
to be available for clinical trials in TNBC in the near future.
Molecular Targets for TherapyePARP Inhibition
PARP inhibitors have been studied in breast cancer for some
time with variable results. Initial studies on iniparib were
encouraging,79 but later studies were unable to conﬁrm either1069
Figure 3 Efﬁcacy of neoadjuvant chemotherapy in clinical trials and data sets in patients with TNBC. Treatments included anthracycline (A), doxorubicinþ
cyclophosphamide (AC), doxorubicin (Dox), taxane (T), epirubicin (E), cyclophosphamide (C), docetaxel (Doc), paclitaxel (Pac), bevacizumab (Bev), gemcitabine
(G), methotrexate (M), 5-FU (F), capecitabine (X), vincristine (V), cisplatin (Cis), and carboplatin (Carb). For the percentage of pathologic complete response
(pCR), black,>100 TN patients in the trial; hatched,>30 TN patients in the trial; and white, 11 to 30 TN patients in the trial. References 59, 61, 62, 63, 64, 65, 66,
67, 68, 69, 70, 71, 72, 73, and 74. *pCR (ductal carcinoma in situ was not allowed). yAll tumors were basal-like. zSeventeen Her2þ patients received trastuzumab.
Engebraaten et althe speciﬁc inhibition or the clinical relevance. The PARP
inhibitor olaparibwas shown to have signiﬁcant activitywhen
given as monotherapy in patients with advanced breast cancer
and veriﬁed BRCAmutations.80 This agent also has been used
in another study with 8 BRCA mutated and 15 TNBC
patients, but with disease stabilization as the best response.81
Thus, monotherapy with these agents is not sufﬁcient and
further trials are needed for selection of the patient population
and appropriate combination regimens for optimal disease
control.82 Therapy combining PARP inhibition and chemo-
therapy has been challenging owing to toxicity, but is
currently in clinical trials (NCT01506609). New combina-
tions involving speciﬁc inhibition of signaling pathways may
be needed to optimize the effect of these agents, as described
in a preclinical study in which phosphatidylinositol 3-kinase
and PARP inhibition were combined.83 A total of 20% of
patients with basal-like tumors recently were found to have
either germline or somatic BRCA1 or BRCA2 dysfunction,
suggesting that one in ﬁve patients with basal-like tumors
might beneﬁt from PARP inhibition.10
Molecular Targeting of Signaling Pathways
The extensive studies on further TNBC subtyping may guide
selection of therapeutics, as indicated in the previously1070discussed studies of gene expression patterns in TNBC.35,84
In addition, sequencing studies of breast cancer are power-
ful tools for the detection of putative targeted therapeutic
approaches for the evaluation and selection of agents9,10,41,56
(Figure 2B).
Targeting the PI3K/mTOR/S6 Pathway and the receptor
tyrosine kinase/RAS/MEK/MAPK Pathway
Activity of the PIK3CA/mTOR/S6 pathway as a driver in
a subset of TNBC has been shown35,84 with veriﬁed PIK3CA
mutations in 10% to 21% of TNBCs (Table 1).10,41,54
Mutations and loss of PTEN (1% to 8% mutated) and
INPP4B (inositol polyphosphate-4-phosphatase, type II, 105
kDa) support the importance of this pathway in TNBC.
Targeting is possible through inhibition of phosphatidylino-
sitol 3-kinase by small molecular inhibitors, or combined
inhibitors targeting other key pathway nodes. Optimal
combinations need to be established to address the observed
tumor heterogeneity and the redundancy of the cell signaling
pathways. Recent results describing mutations in several
other targets including tyrosine kinases and RAS may indi-
cate that certain tumors may be candidates for inhibition of
the RAS/RAF/MEK/ERK pathway for effective growth
inhibition. However, direct targeting of upstream tyrosine
kinases, in particular EGFR, which has been found ampliﬁedajp.amjpathol.org - The American Journal of Pathology
TNBC and Therapeutic Targetsand up-regulated in TN tumors, have been the focus of recent
clinical studies with disappointing results.85,86 Targeting
downstream in the signaling pathway may be more effective,
and studies are ongoing on the value of MEK inhibition in
TNBC (Figure 2B). Inhibiting such a pathway, however, may
trigger compensatory responses, as recently investigated.87 A
rational selection of targets therefore may be necessary to
ensure optimal treatment efﬁcacy.
Targeting the Rb/Proliferation Gene Pathways
Mutations and aberrations affecting gene expression in the
Rb pathway are a highly relevant and signiﬁcant feature of
TNBC.9,10 This is conﬁrmed by RNA expression studies,
with tumors overexpressing kinases related to cell-cycle
and DNA replication.35,84 High proliferative capacity is
a hallmark of these TN tumors, with a dismal prognosis. A
number of targets are druggable in this setting, exempliﬁed
by aurora kinase and polo-like kinase, in addition to more
nonspeciﬁc inhibition by targeting heat shock protein 90.
MYC is associated with basal-like breast cancer and was
found ampliﬁed in approximately 30% of basal-like breast
cancers in the Cancer Genome Atlas Network data set.10
CDK inhibition is a possible therapeutic targeting strategy
in MYC-activated basal-like breast cancers.88 FOXM1 is
a driver in basal-like breast cancers, which strengthens the
argument that such growth-promoting pathways should be
targeted for therapy.10,57Targeting the Cytoskeleton, Cell Migration, and
Vascular System
Mutations affecting the cytoskeleton,41 and thus possibly
inﬂuencing EMT, have been observed relatively frequently in
TNBC.89,90 Both basal-like and in particular claudin-low
tumors have high expression levels of proteins involved in
the EMT process.32,85 The tyrosine kinase Src is involved in
cell migration, and therefore may be one target for therapy
involving the EMT and cell migration.35 The efﬁcacy of src
inhibition in TNBC using dasatinib recently was investigated,
butwith limited activity.91However,monotherapy using such
targeted agents is not expected to be highly active, and
optimal therapeutic combinations in addition to markers for
selecting responsive tumors should be sought for this thera-
peutic approach in TNBC. Subgroups of these tumors also
show high expression levels of stem celleassociated markers
that may confer resistance to conventional therapy. Targeting
the EMT process thus may be important for a subset of
TNBCs. The ﬁnding that genes coding for proteins that are
important in extracellular matrix dynamics, receptors, and
pathways associated with vascular endothelial growth factor
signaling are affected in TNBC indicate that microenviron-
mental interactions may be of crucial importance for the
development and progression of these tumors.10,92 Such
interactions also may constitute targets for therapy. Inhibition
of angiogenesis has been suggested as a target in TNBC, andThe American Journal of Pathology - ajp.amjpathol.orgalthough initial positive results have been obtained,61,62 the
development of markers for selecting appropriate patients for
antiangiogenic therapy are highly needed.
Conclusions
Heterogeneity of TNBC is widely acknowledged and is
evident in both molecular and clinical studies. The large
amount of information evolving from high-throughput
molecular analyses including sequencing, represents an
even more detailed basis for understanding the molecular
biology of TNBC, but at the same time emphasizes the tumor
heterogeneity and the continuous alterations associated with
tumor evolution. How this translates to the molecular biology
of metastatic disease only partially is understood and needs
further study. New discoveries will generate opportunities for
novel treatment strategies, as well as more rational selection
of patients for existing treatment regimens. Future clinical
studies should be designed for a better understanding of the
relationship between the molecular biology and therapy
response, in addition to traditional clinical end points.References
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